ClinicalTrials.gg
CompletedNCT00778921Updated Oct 27, 2016Results posted

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

A Phase 3 interventional study of Amlodipine 10 mg and Aliskiren 150 in Hypertension, sponsored by Novartis. Completed at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
847
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
30th of 186
847 · median 180
Started
2008
with 13 others
Phase 3
69 of 187
2 open now
Registered
67th of 187
by date
Lead sponsor
40 of 187
Novartis

Among the 187 studies testing amlodipine in Hypertension, this one is the 30th largest by enrollment of the 186 interventional ones that give a count, is one of 14 that started in 2008, is one of 69 in phase 3, and was the 67th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Aliskiren
  • Amlodipine
  • Non-responder to Amlodipine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 95 mmHg and \< 110 mmHg at Visits 1 and 2
  • Patients who have been treated for hypertension within the 4 weeks prior to Visit 1 must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 2
  • All patients must have a msDBP ≥ 90 mmHg and \< 110 mmHg at Visit 5 (randomization)

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension
  • Pregnant or nursing (lactating) women
  • Pre-menopausal women not taking accepted form of
  • Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1
  • History of cardiovascular conditions
  • Uncontrolled Type 1 or Type 2 diabetes mellitus
  • to renin inhibitors, calcium channel blockers, or to drugs with similar chemical structures

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
847 participants (actual)

Study arms

  • Experimental
    Amlodipine 10 mg

    Amlodipine 10 mg

    Drug: Amlodipine 10 mg

  • Experimental
    Aliskiren/Amlodipine 150/10 mg

    Aliskiren/Amlodipine 150/10 mg

    Drug: Amlodipine 10 mg · Drug: Aliskiren 150

  • Experimental
    Aliskiren/Amlodipine 300/10 mg

    Aliskiren/Amlodipine 300/10 mg

    Drug: Amlodipine 10 mg · Drug: Amlodipine 300

Interventions

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Amlodipine 10 mg

  • DrugAliskiren 150

    Aliskiren/Amlodipine 150/10 mg

  • DrugAmlodipine 300

    Aliskiren/Amlodipine 300/10 mg

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study

    Time frame: Baseline and Week 8

  2. Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group

    Time frame: 8 weeks

  3. Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)

    Time frame: 12 weeks

07

Results

Posted Mar 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneAliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mg
Started279285283
Completed261266255
Not completed181928
Withdrew: Adverse event91014
Withdrew: Abnormal laboratory value(s)100
Withdrew: Abnormal test procedure result(s)002
Withdrew: Unsatisfactory therapeutic response111
Withdrew: Patient no longer requires study drug010
Withdrew: Patient withdrew request316
Withdrew: Lost to follow-up021
Withdrew: Administrative problems120
Withdrew: Protocol violation302
Withdrew: Not treated022

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study
Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study
mm HgAliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study-10.99 ± 0.462-8.95 ± 0.460-7.23 ± 0.459
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study
Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study
mm HgAliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study-14.42 ± 0.684-11.01 ± 0.681-8.20 ± 0.680
SecondaryNumber of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group
Time frame:
8 weeks
Reported as:
Number · Participants
Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group
ParticipantsAliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mg
Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group879992
SecondaryBiomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)
Time frame:
12 weeks

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aliskiren 300mg/ Amlodipine 10mg—4/279 (1.4%)31/279 (11.1%)
Aliskiren 150mg/ Amlodipine 10mg—1/283 (0.4%)35/283 (12.4%)
Amlodipine 10mg—0/281 (0%)40/281 (14.2%)
Most frequent serious events
Most frequent serious events
EventAliskiren 300mg/ Amlodipine 10mgAliskiren 150mg/ Amlodipine 10mgAmlodipine 10mg
Lymphoid tissue hyperplasiaBlood and lymphatic system disorders1/2790/2830/281
Tendon ruptureInjury, poisoning and procedural complications1/2790/2830/281
Renal artery stenosisRenal and urinary disorders1/2790/2830/281
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/2790/2830/281
Joint injuryInjury, poisoning and procedural complications0/2791/2830/281
Most frequent other events
Most frequent other events
EventAliskiren 300mg/ Amlodipine 10mgAliskiren 150mg/ Amlodipine 10mgAmlodipine 10mg
Oedema peripheralGeneral disorders15/27923/28325/281
NasopharyngitisInfections and infestations16/27915/28315/281

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mgTotal
Mean55.2 ± 10.1954.4 ± 10.7054.3 ± 10.9254.6 ± 10.60
Sex: Female, Male
Sex: Female, Male(Participants)Aliskiren/Amlodipine 300/10 mgAliskiren/Amlodipine 150/10 mgAmlodipine 10 mgTotal
Female11611399328
Male163172184519
08

Study locations

7 sites
  • Investigative Site
    Buenos Aires, Argentina
  • Investigative Site
    Berlin, Germany
  • Investigative Site
    Oslo, Norway
  • Investigative Site
    Warsaw, Poland
  • Investigative Site
    Bratislava, Slovakia
  • Investigative Site
    Stockholm, Sweden
  • Investigative Site
    Ankara, Turkey
09

References and documents

Publications

  • Pfeiffer D, Rennie N, Papst CC, Zhang J. Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy yen. Curr Vasc Pharmacol. 2012 Nov;10(6):773-80. doi: 10.2174/157016112803520945. PubMed 22303911 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Oct 24, 2008
Start
Oct 2008
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Mar 23, 2011
Last update
Oct 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00778921
Lead sponsor
Novartis
First posted
Oct 24, 2008
Start date
Oct 2008
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Mar 23, 2011
Last update
Oct 27, 2016

Study contacts

Novartis
study chair · N

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion